BRCA gene structure and function in tumor suppression: A repair-centric perspective

Cancer Journal

Volumn 16, Issue 1, 2010, Pages 39-47

  Murphy, Conleth G ^a   Moynahan, Mary Ellen ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer; BRIP1; DNA damage; DNA double strand break repair; Genetic instability; Homologous recombination; PALB2

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DOUBLE STRANDED DNA; HELICASE; NIBRIN; RAD51 PROTEIN;

ALLELE; BREAST TUMOR; CANCER GENETICS; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL LEVEL; CHROMOSOME ABERRATION; CLINICAL ASSESSMENT; DNA REPAIR; DNA STRAND BREAKAGE; ENZYME ACTIVITY; FANCONI ANEMIA; GENE FUNCTION; GENE MUTATION; GENE REARRANGEMENT; GENE STRUCTURE; GENETIC STABILITY; GENOME; HETEROZYGOTE DETECTION; HOMOLOGOUS RECOMBINATION; HUMAN; NONHUMAN; ORGANISM; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW; TISSUE LEVEL;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA REPAIR; FEMALE; GENES, TUMOR SUPPRESSOR; GERM-LINE MUTATION; HUMANS; PROGNOSIS;

EID: 77149128984     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181cf0204     Document Type: Review

References (120)

1. Pierce AJ, Stark JM, Araujo FD, et al. Double-strand breaks and tumorigenesis. Trends Cell Biol. 2001;11:S52-S59.
2. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913-917.
3. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
4. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-134.
5. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423.
6. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
7. Pierce AJ, Hu P, Han M, et al. Ku DNA end-binding protein modulates homologous repair of double-strand breaks in mammalian cells. Genes Dev. 2001;15:3237-3242.
8. Johnson RD, Jasin M. Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. EMBO J. 2000;19: 3398-3407.
9. Liang F, Han M, Romanienko PJ, et al. Homology-directed repair is a major double-strand break repair pathway in mammalian cells. Proc Natl Acad Sci USA. 1998;95:5172-5177.
10. Elliott B, Richardson C, Winderbaum J, et al. Gene conversion tracts from double-strand break repair in mammalian cells. Mol Cell Biol. 1998;18:93-101.
11. Sung P, Krejci L, Van Komen S, et al. Rad51 recombinase and recombination mediators. J Biol Chem. 2003;278:42729-42732.
12. McCarthy EE, Celebi JT, Baer R, et al. Loss of Bard1, the heterodimeric partner of the Brca1 tumor suppressor, results in early embryonic lethality and chromosomal instability. Mol Cell Biol. 2003;23:5056-5063.
13. Westermark UK, Reyngold M, Olshen AB, et al. BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks. Mol Cell Biol. 2003;23:7926-7936.
14. Takata M, Sasaki MS, Tachiiri S, et al. Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol Cell Biol. 2001;21:2858-2866.
15. Easton DF, Bishop DT, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1993;52:678-701.
16. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250:1684-1689.
17. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266: 66-71.
18. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265: 2088-2090.
19. Chen J, Silver DP, Walpita D, et al. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell. 1998;2:317-328.
20. Scully R, Chen J, Plug A, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997;88:265-275.
21. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature. 1997;386:804-810.
22. Moynahan ME, Chiu JW, Koller BH, et al. Brca1 controls homologydirected DNA repair. Mol Cell. 1999;4:511-518.
23. Moynahan ME, Cui TY, Jasin M. Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 2001;61:4842-4850.
24. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homologydirected repair of chromosomal breaks. Mol Cell. 2001;7:263-272.
25. Tutt A, Bertwistle D, Valentine J, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 2001;20:4704-4716.
26. Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene. 2002;21:8981-8993.
27. Thorslund T, West SC. BRCA2: a universal recombinase regulator. Oncogene. 2007;26:7720-7730.
28. Tirkkonen M, Johannsson O, Agnarsson BA, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 1997;57:1222-1227.
29. Weaver Z, Montagna C, Xu X, et al. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome ampli-fication yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene. 2002;21:5097-5107.
30. Christ N, Moynahan ME, Jasin M. BRCA2: safeguarding the genome through homologous recombination. In: Rothstein R, ed. Molecular Genetics of Recombination. Berlin: Springer; 2007:363-380.
31. Moynahan ME. The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans. Oncogene. 2002;21:8994-9007.
32. Esashi F, Galkin VE, Yu X, et al. Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2. Nat Struct Mol Biol. 2007; 14:468-474.
33. Donoho G, Brenneman MA, Cui TX, et al. Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice. Genes Chromosomes Cancer. 2003;36:317-331.
34. McAllister KA, Bennett LM, Houle CD, et al. Cancer susceptibility of mice with a homozygous deletion in the COOH-terminal domain of the Brca2 gene. Cancer Res. 2002;62:990-994.
35. Esashi F, Christ N, Gannon J, et al. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature. 2005;434:598-604.
36. Yang H, Jeffrey PD, Miller J, et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science. 2002;297: 1837-1848.
37. Saeki H, Siaud N, Christ N, et al. Suppression of the DNA repair defects of BRCA2-deficient cells with heterologous protein fusions. Proc Natl Acad Sci USA. 2006;103:8768-8773.
38. Callebaut I, Mornon JP. From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. FEBS Lett. 1997;400:25-30.
39. Koonin EV, Altschul SF, Bork P. BRCA1 protein products. Functional motifs. Nat Genet. 1996;13:266-268.
40. Glover JN, Williams RS, Lee MS. Interactions between BRCT repeats and phosphoproteins: tangled up in two. Trends Biochem Sci. 2004;29:579-585.
41. Williams RS, Green R, Glover JN. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol. 2001;8:838-842.
42. Yu X, Chini CC, He M, et al. The BRCT domain is a phospho-protein binding domain. Science. 2003;302:639-642.
43. Wang B, Matsuoka S, Ballif BA, et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science. 2007;316: 1194-1198.
44. Wang B, Elledge SJ. Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci USA. 2007;104:20759-20763.
45. Kumaraswamy E, Shiekhattar R. Activation of BRCA1/BRCA2-associated helicase BACH1 is required for timely progression through S phase. Mol Cell Biol. 2007;27:6733-6741.
46. Yu X, Fu S, Lai M, et al. BRCA1 ubiquitinates its phosphorylationdependent binding partner CtIP. Genes Dev. 2006;20:1721-1726.
47. Sartori AA, Lukas C, Coates J, et al. Human CtIP promotes DNA end resection. Nature. 2007;450:509-514.
48. Wu Y, Shin-ya K, Brosh RM Jr. FANCJ helicase defective in Fanconia anemia and breast cancer unwinds G-quadruplex DNA to defend genomic stability. Mol Cell Biol. 2008;28:4116-4128.
49. Scully R, Ganesan S, Vlasakova K, et al. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell. 1999;4:1093-1099.
50. Sy SM, Huen MS, Chen J. PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA. 2009;106:7155-7160.
51. Botuyan MV, Nomine Y, Yu X, et al. Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains. Structure. 2004;12:1137-1146.
52. Clapperton JA, Manke IA, Lowery DM, et al. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nat Struct Mol Biol. 2004;11:512-518.
53. Tischkowitz M, Hamel N, Carvalho MA, et al. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach. Eur J Hum Genet. 2008;16:820-832.
54. Cantor SB, Bell DW, Ganesan S, et al. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell. 2001;105:149-160.
55. Litman R, Peng M, Jin Z, et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell. 2005;8:255-265.
56. Youds JL, O'Neil NJ, Rose AM. Homologous recombination is required for genome stability in the absence of DOG-1 in Caenorhabditis elegans. Genetics. 2006;173:697-708.
57. Eddy J, Maizels N. Gene function correlates with potential for G4 DNA formation in the human genome. Nucleic Acids Res. 2006;34:3887-3896.
58. Zhao Y, Tarailo-Graovac M, O'Neil NJ, et al. Spectrum of mutational events in the absence of DOG-1/FANCJ in Caenorhabditis elegans. DNA Repair (Amst). 2008;7:1846-1854.
59. Cantor S, Drapkin R, Zhang F, et al. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci USA. 2004;101:2357-2362.
60. Sommers JA, Rawtani N, Gupta R, et al. FANCJ uses its motor ATPase to destabilize protein-DNA complexes, unwind triplexes, and inhibit RAD51 strand exchange. J Biol Chem. 2009;284:7505-7517.
61. Eelen G, Vanden Bempt I, Verlinden L, et al. Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy. Oncogene. 2008;27:4233-4241.
62. Chen L, Nievera CJ, Lee AY, et al. Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. J Biol Chem. 2008;283:7713-7720.
63. Yun MH, Hiom K. CtIP-BRCA1 modulates the choice of DNA doublestrand-break repair pathway throughout the cell cycle. Nature. 2009;459: 460-463.
64. Chen PL, Liu F, Cai S, et al. Inactivation of CtIP leads to early embryonic lethality mediated by G1 restraint and to tumorigenesis by haploid insuffi-ciency. Mol Cell Biol. 2005;25:3535-3542.
65. Xia B, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006;22:719-729.
66. Kuznetsov SG, Liu P, Sharan SK. Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2. Nat Med. 2008;14:875-881.
67. Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39:162-164.
68. Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet. 2007;39:159-161.
69. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007; 39:165-167.
70. Oliver AW, Swift S, Lord CJ, et al. Structural basis for recruitment of BRCA2 by PALB2. EMBO Rep. 2009;10:990-996.
71. Zhang F, Fan Q, Ren K, et al. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res. 2009; 7:1110-1118.
72. Zhang F, Ma J, Wu J, et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol. 2009;19:524-529.
73. Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297:606-609.
74. Alter BP, Rosenberg PS, Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet. 2007;44:1-9.
75. Levran O, Attwooll C, Henry RT, et al. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet. 2005;37:931-933.
76. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007;8:735-748.
77. Shen X, Do H, Li Y, et al. Recruitment of fanconi anemia and breast cancer proteins to DNA damage sites is differentially governed by replication. Mol Cell. 2009;35:716-723.
78. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
79. Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38:1239-1241.
80. Erkko H, Dowty JG, Nikkila J, et al. Penetrance analysis of the PALB2 c. 1592delT founder mutation. Clin Cancer Res. 2008;14:4667-4671.
81. Erkko H, Xia B, Nikkila J, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446:316-319.
82. Atchley DP, Albarracin CT, Lopez A, et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26:4282-4288.
83. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482-1485.
84. Palacios J, Honrado E, Osorio A, et al. Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2004;96: 712-714; author reply 714.
85. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998;90:1138-1145.
86. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-271.
87. Bane AL, Beck JC, Bleiweiss I, et al. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol. 2007;31:121-128.
88. Tischkowitz M, Xia B, Sabbaghian N, et al. Analysis of PALB2/FANCNassociated breast cancer families. Proc Natl Acad Sci USA. 2007;104:6788-6793.
89. Heikkinen T, Karkkainen H, Aaltonen K, et al. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res. 2009;15:3214-3222.
90. Garcia MJ, Fernandez V, Osorio A, et al. Analysis of FANCB and FANCN/ PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families. Breast Cancer Res Treat. 2009;113:545-551.
91. Cao AY, Huang J, Hu Z, et al. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat. 2009;114:457-462.
92. Foulkes WD, Ghadirian P, Akbari MR, et al. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res. 2007;9:R83.
93. Sluiter M, Mew S, van Rensburg EJ. PALB2 sequence variants in young South African breast cancer patients. Fam Cancer. 2009;8:347-353.
94. De Nicolo A, Tancredi M, Lombardi G, et al. A novel breast cancerassociated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clin Cancer Res. 2008;14:4672-4680.
95. Lewis AG, Flanagan J, Marsh A, et al. Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Res. 2005;7:R1005-R1016.
96. McInerney NM, Miller N, Rowan A, et al. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort. Breast Cancer Res Treat. September 18, 2009. doi:10.1007/s10549-009-0540-9. Available at: http://www.springerlink.com/content/j606225875814430/.
97. Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007;7:937-948.
98. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676-689.
99. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet. 2008;40:17-22.
100. Narod SA, Foulkes WD. BRCA1 and BRCA2:1994 and beyond. Nat Rev Cancer. 2004;4:665-676.
101. Hendrickson BC, Judkins T, Ward BD, et al. Prevalence of five previously reported and recurrent BRCA1 genetic rearrangement mutations in 20,000 patients from hereditary breast/ovarian cancer families. Genes Chromosomes Cancer. 2005;43:309-313.
102. Myriad Genetics Laboratories I. BRACAnalysis Technical Specifications; 2009. Available at: http://www.myriadtests.com/provider/doc/BRACAnalysis- Technical-Specifications.pdf. Accessed February 2009.
103. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006;295:1379-1388.
104. Staaf J, Torngren T, Rambech E, et al. Detection and precise mapping of germline rearrangements in BRCA1, BRCA2, MSH2, and MLH1 using zoom-in array comparative genomic hybridization (aCGH). Hum Mutat. 2008;29:555-564.
105. National Human Genome Research Institute. An open access on-line breast cancer mutation data base. Available at: http://research.nhgri.nih.gov/bic/.
106. Chang S, Biswas K, Martin BK, et al. Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. J Clin Invest. 2009;119:3160-3171.
107. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994;266:120-122.
108. Esteller M, Silva JM, Dominguez G, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564-569.
109. Matros E, Wang ZC, Lodeiro G, et al. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat. 2005;91:179-186.
110. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26:2126-2132.
111. Ganesan S, Silver DP, Greenberg RA, et al. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell. 2002;111:393-405.
112. Richardson AL, Wang ZC, De Nicolo A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9:121-132.
113. Beger C, Pierce LN, Kruger M, et al. Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci USA. 2001;98:130-135.
114. Potapova A, Hoffman AM, Godwin AK, et al. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res. 2008;68:998-1002.
115. Jonsson G, Naylor TL, Vallon-Christersson J, et al. Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res. 2005;65:7612-7621.
116. van Beers EH, van Welsem T, Wessels LF, et al. Comparative genomic hybridization profiles in human BRCA1 and BRCA2 breast tumors highlight differential sets of genomic aberrations. Cancer Res. 2005;65:822-827.
117. Stefansson OA, Jonasson JG, Johannsson OT, et al. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res. 2009;11:R47.
118. Stark JM, Pierce AJ, Oh J, et al. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biol. 2004;24:9305-9316.
119. Hughes-Davies L, Huntsman D, Ruas M, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell. 2003;115:523-535.
120. Raouf A, Brown L, Vrcelj N, et al. Genomic instability of human mammary epithelial cells overexpressing a truncated form of EMSY. J Natl Cancer Inst. 2005;97:1302-1306.